Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.32 |
| ▸ | RELA | Q04206 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.31 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1514137 | 0.93 | GRIN2B (0.32) | ELANENFKB1NFKB2RELAGRIN2B | |
| SCHEMBL12482671 | 0.83 | GRIN2B (0.35) | ELANELMNACA1CA2CA7 | |
| SCHEMBL22151991 | 0.77 | LMNA (0.43) | KMT2ALMNACHRM2CHRM1CHRM3 | |
| SCHEMBL15623779 | 0.75 | RAB9A (0.41) | SLC1A2KMT2AATMLMNACHRM2 | |
| SCHEMBL542300 | 0.75 | RAB9A (0.41) | SLC1A2KMT2AATMLMNACHRM2 | |
| SCHEMBL9530404 | 0.75 | GLA (0.31) | ELANE | |
| SCHEMBL542373 | 0.73 | TP53 (0.55) | ELANEKMT2ALMNAGAA | |
| SCHEMBL1289807 | 0.72 | ALDH1A1 (0.37) | KMT2ALMNACA1CA2CA7 | |
| SCHEMBL3736109 | 0.71 | ALDH1A1 (0.35) | KMT2ALMNACA1CA2CA7 | |
| SCHEMBL242269 | 0.71 | MGLL (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | FRANKLIN RICHARD (GB) | 2012-08-09 | — | — | US | disclosed |
| CN-102573845-A | Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof | SHIRE LLC | 2012-07-11 | — | — | CN | disclosed |
| WO-2012046062-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | SHIRE, LLC (US) | 2012-04-12 | — | — | WO | disclosed |
| EP-2413937-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | Shire LLC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2010112942-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | VIP, OPRL1, OPRK1 | ELANE 3566/4885SLC1A2 27/4885NFKB1 1715/4885 |
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | OPRM1, UGT1A6, UGT1A4 | ELANE 2437/4885SLC1A2 332/4885NFKB1 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.